Gefitinib 250 mg/1 (Gefitinib TABLET, FILM COATED) 250 mg/1

Gefitinib 250 mg tablets are a targeted therapy used in cancer treatment. This oral medication is designed to inhibit specific proteins that contribute to cancer cell growth.

Strength

250 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE (0480-4053-56)

Manufacturer / TM Owner

Teva Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Gefitinib is primarily used in the treatment of certain types of non-small cell lung cancer. It works by targeting and blocking proteins that help cancer cells grow and spread. This medication is often prescribed for patients with specific genetic mutations that make their cancer cells more responsive to Gefitinib. It is important to consult a healthcare provider to determine if Gefitinib is suitable for your condition.

Side Effects

Common effects of Gefitinib may include skin rash, diarrhea, and dry skin. Some patients may also experience nausea, loss of appetite, and fatigue. These effects vary among individuals and may not affect everyone who takes the medication.

Precautions & Warnings

Gefitinib should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by your healthcare provider. Inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Avoid Interactions

Gefitinib may interact with certain medications, including those that are metabolized by the liver. It is important to discuss all current medications with your healthcare provider before starting Gefitinib. Avoiding alcohol and certain foods that may affect liver function is also advisable.

Frequently Asked Questions

Gefitinib is used to treat certain types of non-small cell lung cancer, particularly in patients with specific genetic mutations.

Gefitinib is typically taken orally, usually once daily. Follow the instructions provided by your healthcare provider for the best results.

Common side effects may include skin rash, diarrhea, dry skin, nausea, loss of appetite, and fatigue.

Gefitinib may interact with certain medications. Consult your healthcare provider before combining it with other treatments.

The safety of long-term use depends on individual health conditions. Always follow your healthcare provider's advice regarding duration of treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.